"16 | TerbuthylazineCAS No 5915-41-3CIPAC No 234 | N2-tert-butyl-6-chloro-N4-ethyl-1,3,5-triazine-2,4-diamine | ≥ 950 g/kgImpurities:- Propazine not more than 10 g/kg
- Atrazine not more than 1 g/kg
- Simazine not more than 30 g/kg
| 1 January 2012 | 31 December 2021 | PART AOnly uses as herbicide may be authorised.PART BFor the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on terbuthylazine, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 17 June 2011 shall be taken into account.In this overall assessment Member States shall pay particular attention to:- (a)the protection of groundwater, when the active substance is applied in regions with vulnerable soil and/or climatic conditions;
- (b)the risk to mammals and earthworms.
Conditions of use shall include risk mitigation measures and the obligation to carry out monitoring programmes to verify potential groundwater contamination in vulnerable zones, where appropriate.The applicant shall submit confirmatory information as regards:- (1)the specification of the technical material, as commercially manufactured, by appropriate analytical data, including information on the relevance of the impurities;
- (2)the equivalence between the specifications of the technical material, as commercially manufactured, and the specifications of the test material used in the toxicity studies;
- (3)groundwater exposure assessment for the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6;
- (4)the relevance of the metabolites MT1 (N-tert-butyl-6-chloro-1,3,5-triazine-2,4-diamine), MT 13 (4-(tert-butylamino)-6-(ethylamino)-1,3,5-triazin-2-ol or 6-hydroxy-N2-ethyl-N4-tert-butyl-1,3,5-triazine-2,4-diamine), MT14 (4-amino-6-(tert-butylamino)-1,3,5-triazin-2-ol or N-tert-butyl-6-hydroxy-1,3,5-triazine-2,4-diamine), and of the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6 with respect to cancer, if terbuthylazine is classified under Regulation (EC) No 1272/2008 as "suspected of causing cancer".
The applicant shall submit to the Commission, the Member States and the Authority the information set out in points (1) and (2) by 30 June 2012, the information set out in point (3) by 30 June 2013 and the information set out in point (4) within six months from the notification of the classification decision concerning that substance." |